Canada markets closed
  • S&P/TSX

    19,366.69
    +230.88 (+1.21%)
     
  • S&P 500

    4,173.85
    +61.35 (+1.49%)
     
  • DOW

    34,382.13
    +360.68 (+1.06%)
     
  • CAD/USD

    0.8263
    +0.0040 (+0.49%)
     
  • CRUDE OIL

    65.51
    +1.69 (+2.65%)
     
  • BTC-CAD

    57,687.46
    -4,209.25 (-6.80%)
     
  • CMC Crypto 200

    1,398.33
    +39.77 (+2.93%)
     
  • GOLD FUTURES

    1,844.00
    +20.00 (+1.10%)
     
  • RUSSELL 2000

    2,224.63
    +53.68 (+2.47%)
     
  • 10-Yr Bond

    1.6350
    -0.0330 (-1.98%)
     
  • NASDAQ

    13,429.98
    +304.99 (+2.32%)
     
  • VOLATILITY

    18.81
    -4.32 (-18.68%)
     
  • FTSE

    7,043.61
    +80.28 (+1.15%)
     
  • NIKKEI 225

    28,084.47
    +636.46 (+2.32%)
     
  • CAD/EUR

    0.6799
    -0.0003 (-0.04%)
     

Global Biosimilar Monoclonal Antibodies Forecast 2020-2030

ReportLinker
·1 min read

Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab. • Global Biosimilar Monoclonal Antibodies Market forecasts from 2017-2027.

New York, April 14, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Biosimilar Monoclonal Antibodies Forecast 2020-2030" - https://www.reportlinker.com/p04974736/?utm_source=GNW
• Along with revenue prediction for the overall world market for biosimilar monoclonal antibodies, our investigation shows forecasts to 2027 for the market segmented by compound:
• Infliximab
• Rituximab
• Abciximab
• Trastuzumab
• Adalimumab
• Bevacizumab

• This report also shows revenue to 2027 for individual biosimilar mAb products in the market:
• Remsima/Inflectra
• Infimab
• Reditux
• BI695500
• CT-P10
• BI695501
• FKB327
• FKB238
• Mabtas
• AcellBia
• Maball
• Clotinab
• Abcixirel
• BCD-022
• BCD-021
• Herzuma
• CANMAB/Hertraz

• Our analyses show individual revenue forecasts to 2027 for these regional and national markets:
• The US Biosimilar mAb Market
• Japanese Biosimilar mAb Market
• EU5 Biosimilar mAb Markets
• BRIC and South Korea Biosimilar mAb Markets
• Rest of the World Biosimilar mAb Market

• This report profiles 10 leading companies either with biosimilar mAbs already on the market or in the pipeline

• Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market
Read the full report: https://www.reportlinker.com/p04974736/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001